Salih Tunbekici

10PUBLICATIONS
130CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Nov 17, 2025
Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel

|Oct 28, 2025
Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel

|Oct 28, 2025
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Gokhan Sahin, Sercan Ön

|Sep 19, 2025
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.

Gökhan Şahin, Esmanur Kaplan Tüzün, Halil G Güzel

|Aug 21, 2025
Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma.

Gökhan Şahin, Caner Acar, Haydar Çağatay Yüksel

Pageof 2

Frequent Collaborators

7 joint publications

Caner Acar

6 joint publications

Gökhan Şahin

6 joint publications

Haydar Çağatay Yüksel

5 joint publications

Elif Şahin